Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Moderate to Severe Ulcerative Colitis
NCT04613518Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in ulcerative colitis (UC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Percentage of Participants in Clinical Response at 12 weeks, Number of Participants Experiencing Adverse Events (AEs) up to 402 days and 3 more. Started Mar 2021; status: completed.
02
Drugs
deucravacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04613518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613518.